150 related articles for article (PubMed ID: 32277283)
1. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Bagal B; Kumar R; Gaur T; Talreja V; Bonda A; Patkar N; Shetty D; Kowtal P; Subramanian PG; Gupta S; Sarin R; Hasan SK
Med Oncol; 2020 Apr; 37(5):48. PubMed ID: 32277283
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
3. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
Pajares B; Porta J; Porta JM; Sousa CF; Moreno I; Porta D; Durán G; Vega T; Ortiz I; Muriel C; Alba E; Márquez A
BMC Cancer; 2018 Jun; 18(1):647. PubMed ID: 29884136
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature.
Hoffmann L; Möller P; Pedersen-Bjergaard J; Waage A; Pedersen M; Hirsch FR
Ann Oncol; 1995 Oct; 6(8):781-8. PubMed ID: 8589015
[TBL] [Abstract][Full Text] [Related]
6. Screening of
Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S
J Med Genet; 2019 Feb; 56(2):63-74. PubMed ID: 30472649
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
9. Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.
Hasan SK; Ottone T; Schlenk RF; Xiao Y; Wiemels JL; Mitra ME; Bernasconi P; Di Raimondo F; Stanghellini MT; Marco P; Mays AN; Döhner H; Sanz MA; Amadori S; Grimwade D; Lo-Coco F
Genes Chromosomes Cancer; 2010 Aug; 49(8):726-32. PubMed ID: 20544846
[TBL] [Abstract][Full Text] [Related]
10. Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Rizza R; Hackmann K; Paris I; Minucci A; De Leo R; Schrock E; Urbani A; Capoluongo E; Gelli G; Concolino P
Mol Diagn Ther; 2019 Feb; 23(1):121-126. PubMed ID: 30506513
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
12. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
[TBL] [Abstract][Full Text] [Related]
13. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
[TBL] [Abstract][Full Text] [Related]
14. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D
N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534
[TBL] [Abstract][Full Text] [Related]
16. Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23).
Hasan SK; Barba G; Metzler M; Divona M; Ottone T; Cicconi L; Falini B; Mecucci C; Lo-Coco F
Genes Chromosomes Cancer; 2014 Mar; 53(3):248-54. PubMed ID: 24310817
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
Concolino P; Rizza R; Hackmann K; Paris I; Minucci A; De Paolis E; Scambia G; Zuppi C; Schrock E; Capoluongo E
Breast Cancer Res Treat; 2017 Jul; 164(2):497-503. PubMed ID: 28488140
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
Jamard E; Volard B; Dugué AE; Legros A; Leconte A; Clarisse B; Davy G; Polycarpe F; Dugast C; Abadie C; Frebourg T; Tinat J; Tennevet I; Layet V; Joly F; Castéra L; Berthet P; Vaur D; Krieger S
Fam Cancer; 2017 Apr; 16(2):167-171. PubMed ID: 27783335
[TBL] [Abstract][Full Text] [Related]
20. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias.
Cimino G; Rapanotti MC; Biondi A; Elia L; Lo Coco F; Price C; Rossi V; Rivolta A; Canaani E; Croce CM; Mandelli F; Greaves M
Cancer Res; 1997 Jul; 57(14):2879-83. PubMed ID: 9230194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
